OncoMatch/Clinical Trials/NCT06205472
Phase II Study of Adjuvant SIB Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.
Is NCT06205472 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
This is a single-arm prospective phase II clinical trial to investigate the efficacy and safety of adjuvant simultaneouslyintegrated boost radiotherapy following narrow-margin(\<1cm) hepatectomy in patients with HCC. Eligibility patients will receive IMRT or VMAT to high risk area of tumor bed and tumor bed. The prescription dose to 95% GTVtb boost was planned at 55-60Gy, with PTV 45-50Gy, in 23-25 fractions, mainly depending on the dose constraints of OARs. The primary endpoint is the 3-year OS, the secondary endpoints are disease-free survival, patterns of failure, toxic events and local control rate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Excluded: Stage DISTANT METASTASIS (M1)
No distant metastasis (M0)
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: hepatectomy
Pathological diagnosis of HCC after hepatectomy with narrow pathological margins (< 1 cm)
Cannot have received: abdominal irradiation
Had prior abdominal irradiation
Cannot have received: liver transplantation
Had prior liver transplantation
Lab requirements
Blood counts
Hb≥80g/L, ANC≥1.0x10^9/L, PLT≥50x10^9/L
Kidney function
creatinine(CRE) and blood urea nitrogen(BUN)≤1.5 times ULN
Liver function
alanine transaminase(ALT) and aspartate transaminase(AST) ≤1.5 times ULN; or ALT ≤ULN and AST ≤6 times ULN exclude possibility of heart disease; Child-Push Score: A5-A6
Blood routine examination: Hb≥80g/L, ANC≥1.0x10^9/L, PLT≥50x10^9/L; Hepatic function: alanine transaminase(ALT) and aspartate transaminase(AST) ≤1.5 times ULN; or ALT ≤ULN and AST ≤6 times ULN exclude possibility of heart disease; Child-Push Score: A5-A6; Renal function: creatinine(CRE) and blood urea nitrogen(BUN)≤1.5 times ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify